Carlos Henrique Venturi Ronchi

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (5)

CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer

Cathrin Brisken, Carlos Henrique Venturi Ronchi

The energetic demands of proliferating cells during tumorigenesis require close coordination between the cell cycle and metabolism. While CDK4 is known for its role in cell proliferation, its metabolic function in cancer, particularly in triple-negative br ...

Nature Research2025

biogrowleR: Enhancing Longitudinal Data Analysis

Cathrin Brisken, Giovanna Ambrosini, Andrea Agnoletto, Carlos Henrique Venturi Ronchi, Hazel Margaret Quinn

Time course measurements are used for many applications in biomedical research, ranging from growth curves to drug efficacy testing and high-throughput screening. Statistical methods used to analyze the resulting longitudinal data, such as t-tests or repea ...

Springer Science and Business Media LLC2025

Understanding hormone signaling and its risk on estrogen receptor-positive breast cancer

Carlos Henrique Venturi Ronchi

Next generation sequencing (NGS), in vivo models, and drug screening reshaped research. In breast cancer, transcriptomics plays an important role in subtyping the disease. In vivo models are used to better understand the disease and drug screenings are use ...

EPFL2024

EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology

Cathrin Brisken, Carlos Henrique Venturi Ronchi

Transcriptomics has revolutionized biomedical research and refined breast cancer subtyping and diagnostics. However, wider use in clinical practice is hampered for a number of reasons including the application of transcriptomic signatures as single sample ...

2024

Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

Cathrin Brisken, Carlos Henrique Venturi Ronchi

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the prog-esterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized ...

AMER ASSOC CANCER RESEARCH2023

Page 1 sur 1